Association of biomarkers of enteric dysfunction, systemic inflammation, and growth hormone resistance with seroconversion to oral rotavirus vaccine: A lasso for inference approach.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
08
2023
accepted:
05
10
2023
medline:
20
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
epublish
Résumé
Rotavirus gastroenteritis remains a leading cause of morbidity and mortality despite the introduction of vaccines. Research shows there are several factors contributing to the reduced efficacy of rotavirus vaccines in low- and middle-income settings. Proposed factors include environmental enteric dysfunction (EED), malnutrition, and immune dysfunction. This study aimed to assess the effect of these factors on vaccine responses using a machine learning lasso approach. Serum samples from two rotavirus clinical trials (CVIA 066 n = 99 and CVIA 061 n = 124) were assessed for 11 analytes using the novel Micronutrient and EED Assessment Tool (MEEDAT) multiplex ELISA. Immune responses to oral rotavirus vaccines (Rotarix, Rotavac, and Rotavac 5D) as well as a parenteral rotavirus vaccine (trivalent P2-VP8) were also measured and machine learning using the lasso approach was then applied to investigate any associations between immune responses and environmental enteric dysfunction, systemic inflammation, and growth hormone resistance biomarkers. Both oral and parenteral rotavirus vaccine responses were negatively associated with retinol binding protein 4 (RBP4), albeit only weakly for oral vaccines. The parenteral vaccine responses were positively associated with thyroglobulin (Tg) and histidine-rich protein 2 (HRP2) for all three serotypes (P8, P6 and P4), whilst intestinal fatty acid binding protein (I-FABP) was negatively associated with P6 and P4, but not P8, and soluble transferrin receptor (sTfR) was positively associated with P6 only. MEEDAT successfully measured biomarkers of growth, systemic inflammation, and EED in infants undergoing vaccination, with RBP4 being the only analyte associated with both oral and parenteral rotavirus vaccine responses. Tg and HRP2 were associated with responses to all three serotypes in the parenteral vaccine, while I-FABP and sTfR results indicated possible strain specific immune responses to parenteral immunization.
Sections du résumé
BACKGROUND
BACKGROUND
Rotavirus gastroenteritis remains a leading cause of morbidity and mortality despite the introduction of vaccines. Research shows there are several factors contributing to the reduced efficacy of rotavirus vaccines in low- and middle-income settings. Proposed factors include environmental enteric dysfunction (EED), malnutrition, and immune dysfunction. This study aimed to assess the effect of these factors on vaccine responses using a machine learning lasso approach.
METHODS
METHODS
Serum samples from two rotavirus clinical trials (CVIA 066 n = 99 and CVIA 061 n = 124) were assessed for 11 analytes using the novel Micronutrient and EED Assessment Tool (MEEDAT) multiplex ELISA. Immune responses to oral rotavirus vaccines (Rotarix, Rotavac, and Rotavac 5D) as well as a parenteral rotavirus vaccine (trivalent P2-VP8) were also measured and machine learning using the lasso approach was then applied to investigate any associations between immune responses and environmental enteric dysfunction, systemic inflammation, and growth hormone resistance biomarkers.
RESULTS
RESULTS
Both oral and parenteral rotavirus vaccine responses were negatively associated with retinol binding protein 4 (RBP4), albeit only weakly for oral vaccines. The parenteral vaccine responses were positively associated with thyroglobulin (Tg) and histidine-rich protein 2 (HRP2) for all three serotypes (P8, P6 and P4), whilst intestinal fatty acid binding protein (I-FABP) was negatively associated with P6 and P4, but not P8, and soluble transferrin receptor (sTfR) was positively associated with P6 only.
CONCLUSION
CONCLUSIONS
MEEDAT successfully measured biomarkers of growth, systemic inflammation, and EED in infants undergoing vaccination, with RBP4 being the only analyte associated with both oral and parenteral rotavirus vaccine responses. Tg and HRP2 were associated with responses to all three serotypes in the parenteral vaccine, while I-FABP and sTfR results indicated possible strain specific immune responses to parenteral immunization.
Identifiants
pubmed: 37976323
doi: 10.1371/journal.pone.0293101
pii: PONE-D-23-24695
pmc: PMC10656027
doi:
Substances chimiques
Rotavirus Vaccines
0
Vaccines, Attenuated
0
Biomarkers
0
Growth Hormone
9002-72-6
RBP4 protein, human
0
Retinol-Binding Proteins, Plasma
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0293101Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-031759
Pays : United States
Informations de copyright
Copyright: © 2023 Mwila-Kazimbaya et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nutrients. 2022 Nov 26;14(23):
pubmed: 36501067
Lancet. 2014 Jun 21;383(9935):2136-43
pubmed: 24629994
Pediatrics. 2013 Jul;132(1):e25-33
pubmed: 23776114
Vaccine. 2014 May 13;32(23):2740-7
pubmed: 24508336
Vaccine. 2021 Jun 16;39(27):3633-3640
pubmed: 33992437
Lancet Infect Dis. 2020 Jul;20(7):851-863
pubmed: 32251641
EClinicalMedicine. 2021 Nov 15;41:101173
pubmed: 34825149
CMAJ. 2005 Aug 2;173(3):279-86
pubmed: 16076825
PLoS Negl Trop Dis. 2020 Sep 30;14(9):e0008711
pubmed: 32997666
Vaccine. 2017 Oct 27;35(45):6228-6237
pubmed: 28967523
Clin Infect Dis. 2016 May 1;62 Suppl 2:S208-12
pubmed: 27059358
Pediatr Infect Dis J. 2017 Apr;36(4):412-416
pubmed: 27977553
J Infect Dis. 2013 Aug 1;208(3):423-31
pubmed: 23599316
J Infect Dis. 2009 Aug 1;200(3):421-9
pubmed: 19545211
Vaccine. 2016 Jun 8;34(27):3068-3075
pubmed: 27154394
Clin Infect Dis. 2016 May 1;62 Suppl 2:S161-7
pubmed: 27059351
PLoS One. 2016 Mar 14;11(3):e0150100
pubmed: 26974432
Clin Infect Dis. 2016 May 1;62 Suppl 2:S96-S105
pubmed: 27059362
Philos Trans R Soc Lond B Biol Sci. 2015 Jun 19;370(1671):
pubmed: 25964453
Vaccine. 2010 Nov 3;28(47):7501-6
pubmed: 20851087
Endocr Connect. 2019 Apr;8(4):309-317
pubmed: 30822273
PLoS One. 2017 Dec 27;12(12):e0187761
pubmed: 29281659
Hum Vaccin. 2011 Jul;7(7):757-61
pubmed: 21521947
BMC Pediatr. 2017 Jul 11;17(1):156
pubmed: 28693503
Pediatr Infect Dis J. 2021 Dec 1;40(12):1135-1143
pubmed: 34870393
J Infect Dis. 2017 Jan 15;215(2):183-191
pubmed: 27815381
Lancet Infect Dis. 2014 Nov;14(11):1096-1104
pubmed: 25303843
EBioMedicine. 2022 Oct;84:104257
pubmed: 36130475
Vaccine. 2015 Jul 17;33(31):3766-72
pubmed: 26065919
Clin Infect Dis. 2016 May 1;62 Suppl 2:S175-82
pubmed: 27059353
PLoS One. 2017 Dec 28;12(12):e0189351
pubmed: 29284036
Medicina (Kaunas). 2020 Sep 08;56(9):
pubmed: 32911665
Clin Vaccine Immunol. 2017 Jan 5;24(1):
pubmed: 27847365
Vaccine. 2017 Feb 1;35(5):796-801
pubmed: 28057385
PLoS Negl Trop Dis. 2023 Mar 21;17(3):e0011181
pubmed: 36943785
Clin Infect Dis. 2016 Jan 15;62(2):150-6
pubmed: 26349548
BMJ. 2010 Jun 15;340:c2825
pubmed: 20551120
Pediatrics. 2010 Sep;126(3):e506-12
pubmed: 20732946